August 2007 Volume 3, Issue 8

Volume 3, Issue 8 | August 2007

August 2007

In this Issue

News Briefs

Global News

Drug Discovery News Placeholder Image

Decorating old drugs to combat resistance

In a recent issue of the Journal of the American Chemical Society, researchers at the University of Wisconsin-Madison and Milwaukee’s Medical College of Wisconsin described their efforts to bring new life to old antibiotics that are quickly being made obsolete by multidrug-resistant microbes.
Drug Discovery News Placeholder Image

Amgen, Daiichi Sankyo reach deal on bone antibody

Amgen and Daiichi Sankyo Co. Ltd. have announced a collaboration and license agreement for the development and commercialization of denosumab in Japan.
Drug Discovery News Placeholder Image

Opening the coffers

Congress moves toward increasing funding for FDA’s drug efforts
Drug Discovery News Placeholder Image

Delaying the inevitable?

A commonly expressed concern about building new antibiotics on the scaffolds of failing first-generation compounds is that the new drugs typically target the same molecular pathways as the originals and therefore microbes resistant to the old compound will rapidly become resistant to the new ones.

Editor's Focus

Drug Discovery News Placeholder Image

Emptying the drawer of the editorial mind

Here are a few thoughts that rattled around in my mind as I walked the floor of this year’s Drug Discovery and Development of Innovative Therapeutics (DDT) show and conference in Boston recently

Research & Development

Drug Discovery News Placeholder Image

Merck pumps up pipeline

Will purchase NovaCardia for $350 million in stock
Drug Discovery News Placeholder Image

Broad cancer collaboration

Merck shells out $75 million upfront to co-develop Ariad’s mTOR inhibitor for multiple cancer indications
Drug Discovery News Placeholder Image

CHF cohorts

Biogen Idec, Cardiokine to co-develop a new drug for treating congestive heart failure
Drug Discovery News Placeholder Image

A new hope for pain

Tikvah, Apkarian strike licensing agreement for chronic pain treatments

Informatics

Drug Discovery News Placeholder Image

Adapt or die

Cytel and Tourtellotte bring more predictability to adaptive trials
Drug Discovery News Placeholder Image

Planning ahead

New software technologies help Parexel team enhance clinical trial recruitment and execution
Drug Discovery News Placeholder Image

Staying on the alert

Sentrx adds Clintrace pharmacovigilance product to its lineup
Drug Discovery News Placeholder Image

Giving it away for free

NimbleGen to distribute DNASTAR software

Automation & Instrumentation

Drug Discovery News Placeholder Image

Go with the flow

Thar Instruments acquires Berger SFC from Mettler Toledo
Drug Discovery News Placeholder Image

Assay assistants

Nanostream creates new division to create customized assays
Drug Discovery News Placeholder Image

Illumina is striking a vein

Illumina to help consortium illuminate genetic causes of vascular disease
Drug Discovery News Placeholder Image

Turbocharging drug production

Xcellerex works to speed up protein and vaccine manufacturing

Genomics & Proteomics

Drug Discovery News Placeholder Image

Jumping into the RNA fray

Deal with Silence Therapeutics gives AstraZeneca a good foot forward in siRNA research
Drug Discovery News Placeholder Image

Divining origins of diabetes

Researchers identify new gene for type 1 diabetes
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue